Insilico Medicine used generative AI platforms PandaOmics and Chemistry42 to discover and design ISM5939, a highly selective oral ENPP1 inhibitor that modulates the STING pathway for cancer immunotherapy.
Insilico Medicine's ISM5939, an AI-designed oral small molecule targeting ENPP1, has received FDA IND clearance for treating solid tumors, marking a significant milestone in AI-driven drug discovery.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.